Our focus in human health includes pulmonology, a field in which we’re developing a vaccine for COVID-19 disease as well as an anti-fibrotic therapeutic candidate, IBIO-100, for idiopathic pulmonary fibrosis, amongst other indications. Some studies1 have shown that a number of patients recovering from COVID-19 have severe pulmonary fibrosis sequelae. Another high unmet medical need disease area and a therapeutic focus for iBio is oncology. Our oncology pipeline is growing with three new programs entering the portfolio.
In the field of animal health, we’re developing a vaccine candidate, IBIO-400, for classical swine fever, a contagious, often fatal, disease affecting both feral and domesticated pigs. As a part of the program, we’ll seek USDA regulatory approvals, some of which will facilitate expansion into new market segments for our contract manufacturing services.
